Assembly Bio Expands ABI-6250 Clinical Program into Cholestatic Liver Diseases

summarizeSummary

Assembly Biosciences is expanding its ABI-6250 drug candidate into new, high-unmet-need liver disease indications, potentially increasing its market opportunity.

check_boxKey Events

• Clinical Program Expansion

  Assembly Biosciences is expanding the clinical development of its oral entry inhibitor candidate, ABI-6250, into primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).

• Addressing Unmet Medical Need

  PSC currently has no approved therapies, and a significant percentage of PBC patients do not adequately respond to existing treatments, highlighting a substantial market opportunity.

• Phase 2 Studies Planned

  A Phase 2 basket study for PBC and PSC is expected to begin in Q1 2027, following a constructive pre-IND meeting with the FDA.

auto_awesomeAnalysis

This 8-K announces Assembly Biosciences' strategic decision to expand the clinical development of its oral drug candidate, ABI-6250, into primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). This move broadens the potential market for ABI-6250, which is already in development for chronic HDV infection. The expansion is supported by preclinical data and positive Phase 1a results, with Phase 2 studies for these new indications planned for Q1 2027. This is significant as PSC currently has no approved therapies, and many PBC patients do not respond to existing treatments, representing a substantial unmet medical need.